热门资讯> 正文
替代手术非GAAP每股收益为-2.43美元，击败0.05美元
2025-03-20 03:59
- Vicarious Surgical press release (NYSE:RBOT): Q4 Non-GAAP EPS of -$2.43 beats by $0.05.
-
- Operating expenses were $15.0 million for the fourth quarter of 2024, compared to $15.5 million in the corresponding prior year period, a decrease of 3%.
- R&D expenses for the fourth quarter of 2024 were $8.5 million, compared to $8.5 million in the fourth quarter of 2023.
- General and administrative expenses for the fourth quarter of 2024 were $5.5 million, compared to $5.9 million in the fourth quarter of 2023.
- Sales and marketing expenses for the fourth quarter of 2024 were $1.0 million, compared to $1.2 million in the fourth quarter of 2023.
More on Vicarious Surgical
- Vicarious Surgical Inc. (RBOT) Q4 2024 Earnings Call Transcript
- Vicarious Surgical Non-GAAP EPS of -$2.43 beats by $0.26
- Seeking Alpha’s Quant Rating on Vicarious Surgical
- Historical earnings data for Vicarious Surgical
- Financial information for Vicarious Surgical
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
